Deloitte is cutting GLP-1 coverage for weight loss and raising health insurance costs for US staff
The Big Four consulting and accounting firm told staff it was "untenable" for Deloitte to carry the weight of rising healthcare costs alone.
Deloitte is reducing coverage for GLP-1 weight loss medication and increasing healthcare costs for its US employees, according to a leaked internal document. The company is no longer covering GLP-1 medication for weight loss through its medical plans, starting in January. Additionally, employees will face higher deductibles and out-of-pocket maximums on most health plans, leading to increased out-of-pocket costs.
Despite these changes, GLP-1 medication will still be covered for diabetes and other covered medical conditions. Deloitte is offering an alternative virtual lifestyle program called eMed, with coaching and a $125-per-prescription employer contribution for those seeking weight loss support. The company attributes the changes to the unsustainable costs of healthcare, stating that they are taking shared responsibility for these hard trade-offs.
Deloitte's US employees are joining a growing list of workers facing higher and less generous healthcare benefits.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- GLP-1 drugs for weight loss linked to vision loss economictimes.indiatimes.com
